EGFR and vascular endothelial growth factor (VEGF) share common downstream signaling pathways (PI3K/AKT and RAS/RAF/ERK) and can function independently during oncogenesis and acquired therapeutic resistance, particularly in EGFR‐mutant NSCLC. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.